文献リスト

1) Hermans J, et al. Adjuvant therapy after curative resection for gastric cancer: meta-analysis of randomized trials. J Clin Oncol. 1983; 11: 1441-7

2) Nakajima T, et al. Meta-analysis of adjuvant chemotherapy trials for gastric cancer at the Cancer Institute Hospital. Tokyo: Springer Verlag; 1999. p. 27-31

3) Earle CC, Maroun JA. Adjuvant chemotherapy after curative resection for gastric cancer in non-Asian patients: revisiting a meta-analysis of randomized trials. Eur J Cancer. 1999; 35: 1059-64

4) Oba K, Morita S, Tsuburaya A, et al. Efficacy of adjuvant chemotherapy using oral fluorinated pyrimidines for for curatively resected gastric cancer: A meta-analysis of centrally randomized controlled trials in Japan. J Chemother. 2006; 18: 311-8

5) Nakajima T, Nashimoto A, Kitamura M, et al. Adjuvant mitomycin and fluorouracil followed by oral uracil plus tegafur in serosa-negative gastric cancer: a randomised trial. Lancet. 1999; 354: 273-7

6) Nashimoto A, Nakajima T, Furukawa H, et al. Randomized trial of adjuvant chemotherapy with mitomycin, fluorouracil, and cytosin arabinoside followed by oral fluorouracil in serosa-negative gastric cancer: Japan Clinical Oncology Group 9206-1. J Clin Oncol. 2003; 21: 2282-7

7) Miyashiro H, Furukawa M, Sasako M, et al. No survival benefit with adjuvant chemotherapy for serosa-positive gastric cancer: Randomized trial of adjuvant chemotherapy with cisplatin followed by oral fluorouracil in serosa-positive gastric cancer. Japan Clinical Oncology Group 9206-2. Gastrointestinal Cancers Symposium Abs 4. 2005

8) Sasako M, Yamaguchi T, Kinoshita T, et al. Randomized phase III trial comparing S-1 monotherapy versus surgery alone for stage II/III gastric cancer patients (pts) after curative D2 gastrectomy (ACTS-GC study). Gastrointestinal Cancers Symposium Abs. 2007; 8

9) Kim NK, Park YS, Heo DS, et al. A phase III randomized study of 5-fluorouracil and cisplatin versus 5-fluorouracil, doxorubicin, and mitomycin C versus 5-fluorouracil alone in the treatment of advanced gastric cancer. Cnacer. 1993; 71: 3813-8

10) Boku N, Ohtsu A, Shimada Y, et al. Phase II study of a combination of irinotecan and cisplatin against metastatic gastric cancer. J Clin Oncol. 1999; 17: 319-23

11) Webb A, Cunningham D, Scarffe JH, et al. Randomized trial comparing epirubicin, cisplatin, and fluorouracil versus fluorouracil, doxorubicin, and methotrexate in advanced esophagogastric cancer. J Clin Oncol. 1997; 15: 261-7

12) Moiseyenko V, Van Cutsem E, Tjulandin S, et al. Docetaxel-cisplatin-5-FU (DCF) versus cisplatin-5-FU (CF) as first line therapy for gastric cancer: interim analysis results on efficacy and safety in a multicenter randomized phase III study. Proc Am Soc Clin Oncol. 2002; 21: (abstr 587)

13) Maehara Y. S-1 in gastric cancer: a comprehensive review. Gastric Cancer. 2003; 6 (Suppl 1): 2-8

14) Koizumi W, Tanabe S, Saigenji K, et al. Phase I/II study of S-1 combined with cisplatin in patients with advanced gastric cancer. Br J Cancer. 2003; 89: 2207-12

15) Takiuchi H, Narahara H, Tsujinaka T, et al. Phase I study of S-1 combined with irinotecan (CPT-11) in patients with advanced gastric cancer (OGSG 0002). Jpn J Clin Oncol. 2005; 35: 520-5

16) Fujitani K, Narahara H, Takiuchi H, et al. Phase I and pharmacokinetic study of S1 combined with weekly paclitaxel in patients with advanced gastric cancer. Oncology. 2005; 69: 414-20

17) Yoshida K, Ninomiya M, Takakura N, et al. Phase II study of docetaxel and S-1 combination therapy for advanced or recurrent gastric cancer. Clin Cancer Res. 2006; 12: 3402-7

18) Boku N, Yamamoto S, Shirao K, et al. Randomized phase III study of 5-fluorouracil (5-FU) alone versus combination of irinotecan and cisplatin (CP) versus S-1 alone in advanced gastric cancer (JCOG9912). Journal of Clinical Oncology, 2007 ASCO Annual Meeting Proceedings Part I. Vol 25, No. 18S (June 20 Supplement), 2007: LBA4513

19) Narahara H, Koizumi W, Hara T, et al. Randomized phase III study of S-1 alone versus S-1 ＋ cisplatin in the treatment for advanced gastric cancer (The SPIRITS trial) SPIRITS: S-1 plus cisplatin vs S-1 in RCT in the treatment for stomach cancer. Journal of Clinical Oncology, 2007 ASCO Annual Meeting Proceedings Part I. Vol 25, No. 18S (June 20 Supplement), 2007: 4514

20) Grothey A, Sargent D, Goldberg RM, et al. Survival of patients with advanced colorectal cancer improves with the availability of fluorouracil-leucovorin, irinotecan, and oxaliplatin in the course of treatment. J Clin Oncol. 2004; 22: 1209-14

21) Cassidy J, et al. First efficacy and safety results from XELOX-1/NO16966, a randomised 2×2 factorial phase III trial of XELOX vs. FOLFOX ＋ bevacizumab or placebo in first-line metastatic colorectal cancer. Annals Oncol. 2006; 17 suppl 9 (abst#LBA30)

22) De Gramont A, Cervantes A, Andre T, et al. OPTIMOX study: FOLFOX7/LV5FU2 compared to FOLFOX4 in patients with advanced colorectal cancer. Proc Am Soc Clin Oncol. 2004; 23: 251s (abstr 3525)

23) Maindrault-Goebel F, Lledo G, Chibaudel B, et al. Final results of OPTIMOX2, a large randomized phase II study of maintenance therapy or chemotherapy-free intervals (CFI) after FOLFOX in patients with metastatic colorectal cancer (MRC): A GERCOR study. Proc ASCO. 2007; 25: 18S (abst#4013)

24) Hurwitz H, Fehrenbacher L, Cartwright T, et al. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med. 2004; 350: 2335-42

25) Giantonio BJ, Catalano PJ, Meropol NJ, et al. High-dose bevacizumab improves survival when combined with FOLFOX4 in previously treated advanced colorectal cancer: Results from the Eastern Cooperative Oncology Group (ECOG) study E3200. Proc ASCO. 2005; 23: 1S (abst#2)

26) Cunningham D, Humblet Y, Siena S, et al. Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer. N Engl J Med. 2004; 351: 337-45

27) Diaz Rubio E, Tabernero J, van Cutsem E, et al. Cetuximab in combination with oxaliplatin/5-fluorouracil (5-FU)/folinic acid (FA) (FOLFOX-4) in the first-line treatment of patients with epidermal growth factor receptor (EGFR)-expressing metastatic colorectal cancer: An international phase II study. Proc Am Soc Clin Oncol. 2005; 23: 3535

28) Venook A, Niedzwiecki D, Hollis D, et al. Phase III study of irinotecan/5FU/LV (FOLFIRI) or oxaliplatin/5FU/LV (FOLFOX) ± cetuximab for patients (pts) with untreated metastatic adenocarcinoma of the colon or rectum (MCRC): CALGB 80203 preliminary results. Proc ASCO. 2006; 24: 18S (abst#3509)

29) Van Cutsem E, Nowacki M, Lang I, et al. Randomized phase III study of irinotecan and 5-FU/FA with or without cetuximab in the first-line treatment of patients with metastatic colorectal cancer (mCRC): The CRYSTAL trial. Proc ASCO. 2007; 25: 18S (abst#4000)

30) Eng C, Maurel J, Scheithauer W, et al. Impact on quality of life of adding cetuximab to irinotecan in patients who have failed prior oxaliplatin-based therapy: The EPIC trial. Proc ASCO. 2007; 25: 18S (abst#4003)

31) Au H, Karapetis C, Jonker D, et al. Quality of life in patients with advanced colorectal cancer treated with cetuximab: Results of the NCIC CTG and AGITG CO. 17 trial. Proc ASCO. 2007; 25: 18S (abst#4002)

32) Saltz LB, Lenz HJ, Hochster H, et al. Randomized Phase II Trial of cetuximab/bevacizumab/irinotecan (CBI) versus cetuximab/bevacizumab (CB) in irinotecan-refractory colorectal cancer. Proc ASCO. 2005; 23: 16S (abst#3508)

33) Cunningham D, Humblet Y, Siena S, et al. Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer. N Engl J Med. 2004; 351: 337-45

34) Berlin J, Neubauer M, Swanson P, et al. Panitumumab antitumor activity in patients (pts) with metastatic colorectal cancer (mCRC) expressing ＞ 10% epidermal growth factor receptor (EGFr). Proc ASCO. 2006: 24: 18S (abst#3548)

35) NCI homepage: http://www.nci.nih.gov/cancerinfo/pdq/treatment/colon/healthprofessional

36) NCCN Practice Guidelines in Colon Cancer: http://www.nccn.org/professionals/physician_gls

NPO医学中央雑誌刊行会 https://www.jamas.or.jp/ info@jamas.or.jp